Trial Watch: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

Important context

In plain English

The 30-second version

What happened?

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

Why does it matter?

Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

What does this not prove?

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Keep reading for evidence stage, limitations, study details, and sources.

What changed: ClinicalTrials.gov lists A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT07518186) as a Phase 3 interventional cancer study. The registry status is Recruiting, with the record last updated 2026-08-28.

Study snapshot: Phase 3; Recruiting; planned enrollment 700. Conditions listed: Multiple Myeloma. A primary outcome listed by the registry is: Complete Response (CR) or Better.

This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.

Population / Applicability

Studied in: Participants age 18 Years and older with Multiple Myeloma who meet the study-specific registry eligibility criteria. (Adults)

Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.

Full evidence details
Study design
Other / not applicable
Sample size
700
Primary outcome
Complete Response (CR) or Better
Replication
Unknown

Funding & Conflicts

ClinicalTrials.gov lists the lead sponsor as Janssen Research & Development, LLC. Sponsorship is reported for transparency and does not establish efficacy.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-29

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-29

Primary evidence supporting this story

Last reviewed

Related discoveries

Trial Watch: A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

https://cancerdiscoveries.com/discoveries/trial-watch-a-study-comparing-jnj-79635322-and-teclistamab-in-participants-with-relapsed-or-refractory-multiple-myeloma/

Evidence stage: Later-Stage Human

What This Means

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

What This Doesn't Mean

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Why It Matters

Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

Important Limitations

  • Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.

Primary sources

  • ClinicalTrials.gov — NCT07518186 — https://clinicaltrials.gov/study/NCT07518186 (NCT07518186)

Date verified: 2026-08-29

Correction status: No correction or retraction